This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
Rialto, California 92377, United States
Hialeah, Florida 33016, United States
Orlando, Florida 32808, United States
Canton, Ohio 44718, United States
San Antonio, Texas 78215, United States
Participant must be ≥ 18 to ≤ 85 years (inclusive), at the time of signing the informed consent.
Weight ≥ 50kg and BMI ≥ 18 kg/m2 up to < 40 kg/m2.
Male and/or females.
Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Criterion not applicable to this CSP version.
Female participants must not be lactating.
Female participants of childbearing potential who are sexually active with a non-sterilised male partner must agree to use an acceptable method of birth control, from enrolment throughout the study and until at least 4 weeks after the last dose of study intervention.
Capable of giving signed informed consent.
Participants with hepatic impairment only:
Supporting documents confirming that the participant has liver cirrhosis with hepatic impairment must be available.
Diagnosis of chronic and stable hepatic impairment.
Any positive result on screening for serum or plasma hepatitis B surface antigen, hepatitis C antibody, and HIV.
History of substance dependence or a positive screen for drugs of abuse, likely to impact participant safety or compliance with study procedures.
History of alcohol abuse or excessive intake of alcohol in the last 12 months.
Abnormal vital signs, after 10 minutes supine rest at screening or Day -1.
Any clinically important abnormalities in rhythm, conduction or morphology of the resting 12-lead ECG at screening or Day -1:
For female participants only: currently pregnant or breast-feeding.
Participants with hepatic impairment only
Participants with previous transjugular intrahepatic portosystemic shunt (TIPS).
Severe ascites defined as ascites requiring paracentesis and albumin at 4-week intervals or less.
Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
Any evidence of additional severe or uncontrolled systemic disease or laboratory finding that makes it unsafe for the participant to participate in the study.
Change in dose regimen of medically-required medication within the last 2 weeks before pre-study examination.
Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
Clinically relevant hepatic encephalopathy.
Oesophageal variceal bleeding in prior 3 months.
Platelet count < 50 × 109/L and/or neutrophil count < 1.2 × 109/L and/or haemoglobin < 85 g/L.
Post liver transplantation.
History of acute or chronic pancreatitis, or pancreatic amylase or lipase greater than twice the ULN at screening.
Study Contact Info
Contact Listings Owner Form
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment 0 reviewsWrite Your Review
There are no reviews yet.
Write Your Review
Participants will be assigned to one of the following cohorts as per Child-Pugh classification:
Cohort 1: Eight participants with Mild hepatic impairment (Child-Pugh A)
Cohort 2: Eight participants with Moderate hepatic impairment (Child-Pugh B)
Cohort 3: Eight participants with Severe hepatic impairment (Child-Pugh C)
Cohort 4: Eight to twelve participants with Normal hepatic function
A final safety follow-up visit on Day 21 will be there after all procedures are completed on Day 15.